glaxosmithkline plc-spon adr
Transactions by GLAXOSMITHKLINE PLC-SPON ADR (GSK) in the last 6 months
Sitari Pharmaceuticals, Inc. announced that it has raised $10 million in its series A round of funding on November 22, 2013. The transaction involved the participation of new investors Avalon Ventures, LLC and GlaxoSmithKline plc.
Suntory Beverage & Food Limited (TSE:2587) entered into an agreement to acquire Lucozade and Ribena brands from GlaxoSmithKline plc (LSE:GSK) for £1.35 billion in cash on September 9, 2013. Annual sales of the two brands in 2012 were £500 million, gross profit of approximately £270 million and total assets of approximately £200 million. The deal was approved by the Board of Directors of Suntory Beverage. The transaction is subject to regulatory approvals and Anti-Monopoly ...
Aspen Pharmacare Holdings Limited (JSE:APN) made an offer to acquire specialised sterile production site at Notre Dame de Bondeville from GlaxoSmithKline plc (LSE:GSK) for £600 million on June 18, 2013. Aspen Pharmacare Holdings Limited entered into an agreement to acquire specialised sterile production site at Notre Dame de Bondeville from GlaxoSmithKline plc for £600 million on September 30, 2013. The deal is suject to acceptance of offer by GlaxoSmithKline, certain ...
|3M Co||$128.61 USD||+1.78|
|Bayer AG||€96.76 EUR||+0.74|
|Gilead Sciences Inc||$73.99 USD||+0.80|
|Merck & Co Inc||$49.39 USD||+0.58|
|View Industry Companies|
Post a JobJobs
- New York, NY | JPMorgan ChasePosted: Dec 06
- Alexandria, VA |Posted: Dec 06
- Detroit, MI | Wayne State UniversityPosted: Nov 26
- New York, NY | AGORAPosted: Nov 25